Nitrase Therapeutics is a pioneering biopharmaceutical company deploying its unique NITROME platform to unlock the therapeutic potential of nitrases, a new class of enzymes that it discovered, to develop a pipeline of therapies against a broad variety of diseases. The medicines that Nitrase Therapeutics is developing will target these enzymes and potentially help slow or halt the progression of a wide variety of diseases in which nitrases and nitro-substrates play a role, including Parkinson’s and cancer. Nitrase Therapeutics (under the former name Nitrome Biosciences) has been widely recognized and has won multiple awards including the prestigious Target Advancement grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF).


Biotechnology

Nitrase Therapeutics

Nitrase Therapeutics' headquarters in Brisbane, CA, United States

Irene Griswold-Prenner

Frank Kayser

James Summers

Eric Yuen

Perry Karsen

Henrijette Richter

Harry Ischiropoulos

Regis B. Kelly

Zach W. Hall

Jonathan Behr

Kalpana Merchant

Stevan W. Djuric

Description

People (4)

Carla Ramos

Sahar Mazhar

Frank Kayser

Sarah Wright

Jobs